Q-omics provides the consensus-scored PMM1 profile across patient tissues and cancer cell-line models. PMM1 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, PMM1 is differentially expressed in 13, with the highest sampling consensus in LUAD. Additionally, PMM1 protein abundance shows 21,729 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UCEC, LUAD, and GBM as cancer lineages where PMM1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PMM1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PMM1 survival associations across molecular data types. PMM1 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (3) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PMM1 RNA expression–survival associations across cancer types. High PMM1 expression shows unfavorable associations in LAML, MESO and KICH, but favorable associations in UCEC, KIRC and UVM. The UCEC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for PMM1 RNA expression.
This table summarizes PMM1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in LUAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PMM1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PMM1 shows lower tumor expression in LUAD, KIRP, COAD, KICH, READ and STAD. The LUAD box plot shows higher PMM1 RNA expression in normal versus tumor tissue (log2 FC = −1.142, t-test p < 0.001).
This table shows molecular features associated with PMM1 in patient tissues and cancer cell lines. In patient samples, PMM1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, PMM1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BONE.
